JADENU 180 MG — DIN 02452227
DEFERASIROX : 180 MG · NOVARTIS PHARMACEUTICALS CANADA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is JADENU?
JADENU 180 MG contains DEFERASIROX : 180 MG. It is listed in the Health Canada Drug Product Database under DIN 02452227, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Mar-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JADENU used for?
JADENU (deferasirox) film-coated tablets is indicated for: • the management of chronic iron overload in patients with transfusion-dependent anemias aged 6 years or older. • the management of chronic iron overload in patients with transfusion-dependent anemias aged two to five who cannot be adequately treated with deferoxamine. • the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Deferasirox cost around the world?
Deferasirox is listed on 19 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 9 | 150 | AUD███.██ |
| Saudi Arabia | public | 23 | 41 | SAR███.██ |
| Greece | producer price (ex-factory) | 28 | 28 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 9 | 25 | EUR███.██ |
| Romania | max producer price | 15 | 21 | RON███.██ |
| Spain | PVP con IVA (public price) | 18 | 18 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 9 | 16 | CZK███.██ |
| United Arab Emirates | public | 15 | 15 | AED███.██ |
| Sweden | AIP (pharmacy purchase price) | 6 | 15 | SEK███.██ |
| United States | acquisition | 2 | 15 | USD███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 3 | 13 | BRL███.██ |
| Austria | KVP (Kassenverkaufspreis) | 9 | 12 | EUR███.██ |
| Slovakia | categorised final price | 12 | 12 | EUR███.██ |
| Bahrain | retail (max) | 3 | 9 | BHD███.██ |
| South Africa | single exit price | 4 | 7 | ZAR███.██ |
| Hungary | producer price (ex-factory) | 6 | 6 | HUF███.██ |
| Luxembourg | reimbursement | 6 | 6 | EUR███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
414 pack listings across 181 brand entries and 17 price bases, refreshed 08 Sep 2026. Ranges span every Deferasirox pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Deferasirox in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Deferasirox, across 45 DINs, of which 36 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 6 | 6 | APO-DEFERASIROX, APO-DEFERASIROX (TYPE J) | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 6 | 6 | EXJADE, JADENU | Sourceable in Canada |
| PHARMASCIENCE INC | 6 | 6 | PMS-DEFERASIROX, PMS-DEFERASIROX (TYPE J) | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 6 | 6 | SANDOZ DEFERASIROX, SANDOZ DEFERASIROX (TYPE J) | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 6 | 6 | TARO-DEFERASIROX, TARO-DEFERASIROX (TYPE J) | Sourceable in Canada |
| AURO PHARMA INC | 3 | 3 | AURO-DEFERASIROX (TYPE J) | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 3 | 3 | JAMP DEFERASIROX (TYPE J) | Sourceable in Canada |
| TEVA CANADA LIMITED | 6 | 0 | TEVA-DEFERASIROX, TEVA-DEFERASIROX (TYPE J) | No marketed DIN |
| JUBILANT GENERICS LIMITED | 3 | 0 | DEFERASIROX (TYPE J) | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 180 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Deferasirox |
|---|---|
| ATC code | V03AC03 |
| AHFS class | 64:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02452227 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2452227 |
| Brand name | JADENU |
| Generic / active ingredient | DEFERASIROX : 180 MG |
| Market authorization holder | NOVARTIS PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | V03AC03 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V03AC |
| Current status | MARKETED |
| Status date | 24-Mar-2016 |
| Original market date | 2016-03-24 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
36 of 45 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DEFERASIROX | 500 MG | TABLET FOR SUSPENSION | APOTEX INC | MARKETED | 02461560 |
| APO-DEFERASIROX | 250 MG | TABLET FOR SUSPENSION | APOTEX INC | MARKETED | 02461552 |
| APO-DEFERASIROX | 125 MG | TABLET FOR SUSPENSION | APOTEX INC | MARKETED | 02461544 |
| APO-DEFERASIROX (TYPE J) | 360 MG | TABLET | APOTEX INC | MARKETED | 02485281 |
| APO-DEFERASIROX (TYPE J) | 180 MG | TABLET | APOTEX INC | MARKETED | 02485273 |
| APO-DEFERASIROX (TYPE J) | 90 MG | TABLET | APOTEX INC | MARKETED | 02485265 |
| AURO-DEFERASIROX (TYPE J) | 360 MG | TABLET | AURO PHARMA INC | MARKETED | 02527790 |
| AURO-DEFERASIROX (TYPE J) | 90 MG | TABLET | AURO PHARMA INC | MARKETED | 02527774 |
| AURO-DEFERASIROX (TYPE J) | 180 MG | TABLET | AURO PHARMA INC | MARKETED | 02527782 |
| EXJADE | 500 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02287447 |
2 · Same class — other molecules in ATC V03AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Deferasirox | APO-DEFERASIROX · APO-DEFERASIROX (TYPE J) · AURO-DEFERASIROX (TYPE J) · DEFERASIROX (TYPE J) · +11 more | 45 | 36 | Yes |
| Deferiprone | FERRIPROX · FERRIPROX MR · TARO-DEFERIPRONE | 5 | 5 | Yes |
| Deferoxamine | DEFEROXAMINE MESYLATE FOR INJECTION · DESFERAL 2G · DESFERAL 500MG · PMS-DEFEROXAMINE | 7 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V03AN | Carbon Dioxide · Combination · Helium · Medical Air · Medical Gases · +2 more | 112 | 43 |
| V03AB | Amyl Nitrite · Andexanet Alfa · Antidotes · Digitalis Antitoxin · Dimercaprol · +16 more | 87 | 31 |
| V03AE | Calcium Acetate · Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia · Lanthanum Carbonate · Patiromer Calcium · Polystyrene Sulphonate · +3 more | 40 | 19 |
| V03AF | Amifostine · Calcium Folinate · Dexrazoxane · Mesna · Palifermin · +1 more | 34 | 16 |
| V03AH | Diazoxide | 2 | 1 |
| V03AX | Cobicistat · Difelikefalin · Other Therapeutic Products | 8 | 1 |
| V03AZ | Ethanol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is JADENU called?
The same molecule, Deferasirox, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Deferasirox Sandoz | Latin | Australia, Czechia, Sweden |
| DEFERAMED | Latin | Australia |
| Deferasirox ARX | Latin | Australia |
| Deferasirox Juno | Latin | Australia |
| DEFERASIROX-TEVA | Latin | Australia |
| Eferas | Latin | Australia |
| Pharmacor Deferasirox FC | Latin | Australia |
| Exjade | Latin | Bahrain, Brazil, Czechia, Morocco, South Africa |
| Pharmacor Deferasirox | Latin | Australia |
| Deferajub | Latin | Saudi Arabia |
| DEFERASIROX | Latin | Brazil |
| Deferasirox Accord | Latin | Czechia, Sweden |
| Deferasirox Glenmark | Latin | Czechia, Sweden |
| Dexrofex | Latin | Saudi Arabia |
| EXFERANA | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.